Last updated: September 13, 2026
Pemigatinib, marketed as Pemazyre in many markets and Truseltiq in the United States, is an oral selective FGFR1-3 inhibitor developed by Incyte. Its commercial value is concentrated in previously treated, FGFR2 fusion or rearrangement-positive intrahepatic cholangiocarcinoma. The drug has a second FDA indication for relapsed or refractory myeloid or lymphoid neoplasms with FGFR1 rearrangement, but that market is substantially smaller.
Pemigatinib reached the U.S. market in 2020 through the accelerated-approval pathway. Its commercial trajectory has been constrained by a biomarker-defined population, competition from futibatinib, limited use in earlier treatment lines, and the withdrawal or transfer of U.S. commercial activities. Incyte’s public reporting does not consistently disclose pemigatinib revenue as a standalone line item, which limits precise product-level valuation.
What is pemigatinib and which patients does it treat?
Pemigatinib is a small-molecule kinase inhibitor that selectively inhibits FGFR1, FGFR2 and FGFR3. Its principal commercial use is in adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma carrying an FGFR2 fusion or rearrangement.
The relevant biomarker is present in a minority of intrahepatic cholangiocarcinoma patients. Published estimates generally place FGFR2 fusions or rearrangements in approximately 10% to 16% of intrahepatic cholangiocarcinoma cases, with lower prevalence across the entire cholangiocarcinoma population [1,2].
| Attribute |
Pemigatinib |
| Active ingredient |
Pemigatinib |
| U.S. brand |
Pemazyre, previously associated with Truseltiq commercial rights |
| Drug class |
Selective FGFR1-3 inhibitor |
| U.S. initial approval |
April 17, 2020 |
| First approved use |
Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement |
| Second U.S. use |
Relapsed or refractory myeloid or lymphoid neoplasms with FGFR1 rearrangement |
| Administration |
Oral tablets, intermittent 21-day cycles |
| Developer |
Incyte |
| U.S. regulatory pathway |
Accelerated approval for cholangiocarcinoma; accelerated approval for FGFR1-rearranged neoplasms |
| Main competitors |
Futibatinib, infigratinib, clinical-trial FGFR inhibitors |
What FDA approvals and regulatory milestones affect pemigatinib?
The FDA approved pemigatinib for cholangiocarcinoma based primarily on the FIGHT-202 study. The trial evaluated patients with previously treated cholangiocarcinoma and demonstrated activity in the FGFR2 fusion or rearrangement subgroup. The confirmed objective response rate in that subgroup was approximately 36%, with a median response duration of about 9.1 months [3].
The FDA later expanded the label to adults with relapsed or refractory myeloid or lymphoid neoplasms harboring an FGFR1 rearrangement. This indication addresses a rare hematologic disease population and has limited direct revenue potential compared with cholangiocarcinoma [4].
Pemigatinib regulatory timeline
| Date |
Event |
| April 2020 |
FDA approved pemigatinib for previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma |
| May 2021 |
FDA approval in Japan for cholangiocarcinoma |
| March 2022 |
FDA approved pemigatinib for relapsed or refractory myeloid or lymphoid neoplasms with FGFR1 rearrangement |
| 2022-2023 |
Commercial responsibility for the U.S. product shifted away from Incyte’s direct commercialization model |
| 2023 onward |
Product remained available through commercial and specialty-pharmacy channels, with regional commercialization arrangements |
The FDA’s accelerated-approval framework made confirmatory evidence important to long-term label durability. Pemigatinib’s confirmatory development has had less commercial visibility than its original registration study because its principal indication is a small biomarker-defined population.
How large is the pemigatinib addressable market?
Pemigatinib’s addressable population is limited by three filters: intrahepatic disease, FGFR2 alteration status and prior treatment. The drug is not a broad cholangiocarcinoma therapy.
A practical U.S. market model is:
| Market filter |
Approximate effect |
| Annual U.S. cholangiocarcinoma incidence |
Several thousand cases |
| Intrahepatic cholangiocarcinoma share |
Roughly 40% to 50% |
| FGFR2 fusion or rearrangement prevalence |
Approximately 10% to 16% of intrahepatic cases |
| Patients reaching second-line treatment |
A minority of diagnosed patients |
| Commercially addressable annual population |
Likely in the low thousands globally and materially below that in the U.S. |
The market is more valuable on a per-patient basis than its volume suggests because pemigatinib is an oncology precision medicine with specialty-distribution economics. Its revenue ceiling remains constrained by diagnosis, biomarker testing, disease progression and competing targeted therapies.
Biomarker testing and market development
Pemigatinib requires molecular testing for FGFR2 fusions or rearrangements in cholangiocarcinoma. Testing has become a commercial bottleneck and a market-enablement factor. Inconsistent adoption of comprehensive genomic profiling can delay treatment selection and reduce the number of patients identified for therapy.
The main testing routes include:
- Next-generation sequencing panels.
- RNA-based fusion testing.
- DNA-based assays capable of detecting rearrangements.
- Laboratory-developed tests and companion-diagnostic platforms.
FGFR2 fusions can be difficult to detect with DNA-only testing, depending on the fusion partner and intronic coverage. RNA-based testing can improve fusion detection, although tissue availability and turnaround time remain operational constraints.
What has been the financial trajectory for pemigatinib?
Pemigatinib generated early commercial growth after its 2020 launch, but public company reporting does not provide a continuous, independently auditable revenue series for the product across all territories.
The U.S. product was commercialized under the Truseltiq name, while Pemazyre is used in other markets. Incyte has reported aggregate product revenue and selected product metrics, but pemigatinib revenue has not consistently appeared as a separate, fully reported global line item in annual filings. This complicates direct comparison with larger Incyte products such as Jakafi and Opzelura.
Commercial trajectory
| Period |
Financial interpretation |
| 2020 |
Launch year; revenue limited by the April approval and specialty launch |
| 2021 |
Initial market expansion in FGFR2-positive cholangiocarcinoma |
| 2022 |
Higher utilization, but still limited by the biomarker-defined population and second-line positioning |
| 2023 onward |
Financial visibility weakened after changes in U.S. commercialization and product-rights structure |
| Long term |
Mature, niche oncology revenue profile rather than a platform-scale growth product |
Earlier public reports indicated that Truseltiq sales grew from a low launch base into the tens of millions of dollars annually. The product did not approach the revenue scale of Incyte’s largest commercial assets. The U.S. rights transfer and regional licensing structure also mean that future pemigatinib economics may appear as royalties, milestone income or partner revenue rather than direct product sales.
Which companies commercialize or license pemigatinib?
Incyte retains the core intellectual-property and development identity for pemigatinib, while regional commercialization has involved partners.
Taiho Pharmaceutical obtained rights in Japan. Taiho Oncology has been associated with U.S. commercialization and distribution activities for Truseltiq following changes in Incyte’s U.S. commercial strategy. European and other international markets have used the Pemazyre brand under Incyte-led or partner-supported arrangements [5,6].
| Company |
Role |
| Incyte |
Originator, principal developer and global intellectual-property holder |
| Taiho Pharmaceutical |
Japan licensee |
| Taiho Oncology |
U.S. commercial role associated with Truseltiq |
| Regional partners |
Market-specific distribution or commercialization roles |
The financial importance of these arrangements is that Incyte can retain economic participation without carrying the full cost of a direct U.S. commercial infrastructure. Royalty-based economics typically produce lower reported product revenue than direct sales but can improve operating leverage.
How does pemigatinib compare with futibatinib and infigratinib?
Pemigatinib competes primarily with futibatinib in FGFR2 fusion-positive cholangiocarcinoma. Infigratinib was another direct competitor, but its U.S. commercial position weakened after manufacturer-led withdrawal of the cholangiocarcinoma indication.
| Product |
Target profile |
Cholangiocarcinoma position |
Key differentiation |
| Pemigatinib |
FGFR1-3 |
Approved for previously treated FGFR2 fusion or rearrangement-positive disease |
First-mover approval and hematologic FGFR1 indication |
| Futibatinib |
Irreversible FGFR1-4 inhibitor |
Approved for previously treated FGFR2 fusion or rearrangement-positive disease |
Irreversible binding and activity after selected prior FGFR therapy |
| Infigratinib |
FGFR2-selective inhibitor |
U.S. indication withdrawn |
Earlier competitive entry but weaker current U.S. position |
Futibatinib’s irreversible mechanism gives it a distinct positioning narrative, particularly in the context of acquired resistance mutations. Pemigatinib remains competitive where clinicians prioritize established use, dosing familiarity and broader FGFR1-3 activity.
The competitive risk is greater in later treatment lines than in first-line therapy because targeted FGFR inhibitors are used after molecular testing and disease progression. Combination regimens and next-generation inhibitors could reduce the duration of pemigatinib treatment over time.
What patents protect pemigatinib?
Pemigatinib is protected by a portfolio covering the active compound, pharmaceutical compositions, dosing regimens and treatment of genetically defined cancers. The earliest U.S. composition-of-matter protection is expected to be more commercially important than later method-of-use patents because it can block generic substitution across approved uses.
Public patent databases and FDA Orange Book records identify multiple U.S. patents associated with pemigatinib. Exact enforceable expiry dates can vary because of patent-term adjustment, patent-term extension, terminal disclaimers and Orange Book listing changes.
Principal patent categories
| Patent category |
Commercial function |
| Compound patents |
Protect pemigatinib and related chemical structures |
| Salt and solid-form patents |
Cover pharmaceutical forms and manufacturability |
| Composition patents |
Protect tablet formulations and drug products |
| Method-of-use patents |
Cover treatment of FGFR2-altered cholangiocarcinoma and FGFR1-rearranged neoplasms |
| Dosing patents |
Protect intermittent dosing schedules and dose-management approaches |
| Manufacturing patents |
Protect synthesis, purification and process controls |
The FDA Orange Book is the controlling public source for listed patents tied to approved U.S. drug products. Pemigatinib’s effective U.S. market protection is likely to extend beyond the five-year new-chemical-entity period because patent protection continues into the 2030s, subject to validity and enforceability [7].
When does pemigatinib lose exclusivity?
Pemigatinib’s regulatory exclusivity and patent exclusivity have different end dates.
The five-year new-chemical-entity exclusivity period began with the April 2020 U.S. approval and expired in April 2025. That date permits submission of an abbreviated new drug application, subject to applicable regulatory requirements. It does not automatically permit commercial generic launch.
Orphan-drug exclusivity for the original cholangiocarcinoma indication generally runs for seven years from approval, potentially extending through April 2027. The FDA’s orphan exclusivity framework prevents approval of the same drug for the same disease or condition during that period, subject to statutory exceptions [8].
Patent protection may extend beyond 2027. The principal commercial question is whether an ANDA applicant can invalidate, design around or otherwise avoid the listed patents. Later method-of-use patents may be challenged through a paragraph IV certification, while compound patents create a more substantial launch barrier.
Exclusivity timeline
| Protection |
Approximate end point |
| U.S. NCE exclusivity |
April 2025 |
| Orphan exclusivity for original cholangiocarcinoma indication |
April 2027 |
| Patent protection |
Potentially into the 2030s, depending on patent and term adjustments |
| Generic launch opportunity |
Dependent on ANDA approval, patent litigation and settlement terms |
Have generic companies filed Paragraph IV challenges?
Publicly available information does not establish a broad, commercially material wave of paragraph IV challenges comparable to those affecting large primary-care products. Any pemigatinib ANDA litigation would likely focus on Orange Book-listed compound, formulation or method-of-use patents.
A paragraph IV challenge could produce four outcomes:
- The generic applicant loses patent litigation and remains blocked.
- The patent holder settles for a later launch date.
- The generic applicant wins invalidity or non-infringement claims.
- The FDA approves the ANDA for non-protected uses through a section viii carve-out.
For pemigatinib, the most important generic-launch scenario is a patent settlement or successful challenge against the core composition patent. A method-of-use carve-out could permit narrower generic labeling but would not necessarily remove all practical barriers, because pharmacies and payers may still rely on indication-specific prescribing controls.
Is pemigatinib exposed to biosimilar competition?
No. Pemigatinib is a chemically synthesized small molecule, not a biologic. Biosimilar competition does not apply. The relevant post-exclusivity threat is conventional generic competition through the ANDA pathway.
This distinction matters commercially. Generic entry can be faster and more price-disruptive than biosimilar entry when patent barriers fall, although specialty-oncology distribution, limited volume and payer controls may slow substitution.
What patent litigation and settlement risks affect pemigatinib?
The principal litigation risks are:
- ANDA paragraph IV litigation against the core compound patent.
- Challenges to formulation or solid-form patents.
- Method-of-use litigation concerning FGFR2-positive cholangiocarcinoma.
- Inter partes review or post-grant review of issued U.S. patents.
- Royalty or license disputes involving regional commercialization partners.
No major publicly established settlement has created a known generic launch date for pemigatinib. The absence of a public settlement reduces near-term visibility into generic entry timing.
A litigation event would have an asymmetric financial effect. Because pemigatinib is a niche product, legal costs may be material relative to annual sales, while a successful generic challenge could reduce branded revenue rapidly once multiple suppliers enter.
How strong is the pemigatinib patent estate?
The estate is commercially meaningful but narrower than the estate of a mass-market medicine. Its strongest elements are likely the core compound claims and patents that cover the approved product or essential dosing architecture. Method-of-use claims may be more vulnerable because they depend on biomarker-defined treatment populations and can sometimes be bypassed through labeling strategies.
| Estate factor |
Assessment |
| Core compound protection |
Most important barrier |
| Biomarker-specific use claims |
Valuable but narrower |
| Formulation protection |
Supports lifecycle management |
| Manufacturing protection |
Can complicate supply replication |
| Generic substitution risk |
Low before core patent expiry; rises sharply after a successful challenge |
| Biosimilar risk |
Not applicable |
The commercial strength of the portfolio will depend on claim scope, prosecution history, patent-term adjustments and whether generic applicants can avoid the listed claims. Patent count alone is not a reliable measure of launch protection.
What geographic markets matter most?
The United States is strategically important because it has the highest oncology drug pricing and the most developed molecular-testing infrastructure. Japan is important because Taiho has local commercial capabilities and a strong oncology presence. Europe offers broader geographic reach but generally lower net pricing and more fragmented reimbursement.
Pemigatinib’s global opportunity is influenced by:
- Availability of molecular testing.
- Reimbursement for genomic profiling.
- National health-technology assessment standards.
- Access to specialty oncology centers.
- Local licensing and distribution structures.
- Competition from futibatinib and locally approved FGFR inhibitors.
Markets without routine comprehensive genomic profiling will have lower diagnosis and treatment rates even where regulatory approval exists.
What generic-entry scenarios are most likely?
Scenario 1: Patent-protected continuation
If core patents remain enforceable into the 2030s, pemigatinib can preserve a niche branded market after regulatory exclusivity ends. Revenue would still face erosion from competing branded FGFR inhibitors and treatment sequencing.
Scenario 2: Authorized or settlement-based entry
A settlement could permit a generic launch before the latest listed patent expires. This would create a defined erosion date and could reduce net pricing before complete patent expiry.
Scenario 3: Successful paragraph IV challenge
A successful challenge to core patent claims would create the highest downside risk. Specialty-drug sales can decline quickly once a first generic launches, although the small patient population may limit the number of entrants.
Scenario 4: Narrow indication carve-out
A generic could enter with one or more patented indications removed from its label. The commercial effect would depend on physician prescribing, payer policy and the practical ability to distinguish protected from unprotected use.
What is the investment and commercial outlook for pemigatinib?
Pemigatinib is best viewed as a durable niche oncology asset rather than a major growth driver. Its core strengths are a validated biomarker-defined indication, established clinical use and a patent estate extending beyond regulatory exclusivity. Its constraints are market size, treatment-line positioning, competitive FGFR inhibition and limited standalone financial disclosure.
The product’s future value will depend on four variables:
- Whether earlier-line or combination development expands the treated population.
- Whether futibatinib captures a larger share of FGFR2-positive disease.
- Whether additional patents delay generic entry beyond 2027.
- Whether commercial rights generate meaningful royalties or milestone income for Incyte.
A realistic base case is stable-to-declining niche revenue before patent expiry, with upside only if pemigatinib moves into earlier treatment settings or secures additional biomarker-defined indications.
Key Takeaways
- Pemigatinib is an oral FGFR1-3 inhibitor primarily used for previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma.
- The addressable population is small because only a minority of intrahepatic cholangiocarcinoma patients carry the relevant alteration.
- U.S. NCE exclusivity ended in April 2025; orphan exclusivity for the original indication is expected to run to approximately April 2027.
- Patent protection may extend into the 2030s, making patent litigation and settlement terms more important than regulatory exclusivity alone.
- Pemigatinib faces direct competition from futibatinib and residual competition from infigratinib.
- Biosimilar competition does not apply because pemigatinib is a small molecule.
- Incyte’s public filings do not provide a consistent, standalone global pemigatinib revenue series.
- The asset has niche commercial value, but it is unlikely to become a major revenue pillar without label expansion or earlier-line adoption.
FAQs
What is the annual cost of pemigatinib treatment?
U.S. list pricing has varied by dose, packaging and commercial period. The annual gross cost is in the specialty-oncology range, while net realized revenue depends on payer discounts, specialty-pharmacy arrangements and patient assistance.
Is pemigatinib used for first-line cholangiocarcinoma?
Its principal approved use is previously treated disease. First-line use is generally associated with standard systemic therapy unless a physician uses the product under a separate clinical rationale or trial protocol.
Can pemigatinib treat FGFR3-altered bladder cancer?
Pemigatinib is not broadly approved for FGFR3-altered urothelial cancer. Its commercial label is centered on FGFR2-altered cholangiocarcinoma and FGFR1-rearranged hematologic neoplasms.
What is the difference between Pemazyre and Truseltiq?
They contain the same active ingredient, pemigatinib, but the brand and commercial presentation vary by market and commercialization arrangement.
Does pemigatinib have orphan-drug protection for both major indications?
The original cholangiocarcinoma indication received orphan-drug treatment. The FGFR1-rearranged hematologic indication is also a rare-disease use, but the scope and timing of any orphan exclusivity must be assessed through the FDA’s indication-specific regulatory records.
References
- National Cancer Institute. (2024). Cholangiocarcinoma treatment information. https://www.cancer.gov/types/liver/patient/bile-duct-treatment-pdq
- Abou-Alfa, G. K., et al. (2020). Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. The Lancet Oncology, 21(5), 671-684. https://doi.org/10.1016/S1470-2045(20)30109-1
- U.S. Food and Drug Administration. (2020). FDA grants accelerated approval to pemigatinib for metastatic cholangiocarcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-metastatic-cholangiocarcinoma
- U.S. Food and Drug Administration. (2022). FDA grants accelerated approval to pemigatinib for myeloid/lymphoid neoplasms with FGFR1 rearrangement. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pemigatinib-relapsed-or-refractory-myeloidlymphoid-neoplasms
- Incyte Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://investor.incyte.com/financial-information/sec-filings
- Taiho Pharmaceutical Co., Ltd. (2024). Corporate and product information. https://www.taiho.co.jp/en/
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products
